USFDA issues 3 observations for Granules India Gagillapur facility
Hyderabad: Granules India has recently announced that US Food and Drug Administration (USFDA) has concluded Pre-Approval Inspection (PAI) with three observations at the company's Gagillapur facility.The facility was inspected from 9th January 2023 to 13th January 2023."Please be informed that Company’s Gagillapur facility located at Hyderabad, Telangana, India has completed the US...
Hyderabad: Granules India has recently announced that US Food and Drug Administration (USFDA) has concluded Pre-Approval Inspection (PAI) with three observations at the company's Gagillapur facility.
The facility was inspected from 9th January 2023 to 13th January 2023.
Read also: Granules India, Greenko ZeroC ink pact to enable carbon free energy, green molecule solutions
Granules India is an Indian pharmaceutical manufacturing company that was founded in 1984 named as Triton Laboratories located in Hyderabad, India.
Granules manufactures varieties of drugs including Paracetamol, Ibuprofen, Metformin, and Guaifenesin, on a large scale for customers in the domestic as well as international markets
Read also: Granules India, Greenko ZeroC ink pact to enable carbon free energy, green molecule solutions
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd